Log In
BCIQ
Print this Print this
 

vilanterol (642444) (formerly GW642444)

Also known as: formerly Horizon

  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionLong-acting adrenergic receptor beta 2 agonist (LABA)
Molecular Target Adrenergic receptor beta 2 (ADRB2)
Mechanism of ActionAdrenergic receptor alpha 2 (ADRA2) agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationChronic obstructive pulmonary disease (COPD)
Indication DetailsTreat chronic obstructive pulmonary disease (COPD)
Regulatory Designation
PartnerInnoviva Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$52.1M

$15.8M

$15.8M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/09/2010

$52.1M

$15.8M

$15.8M

Get a free BioCentury trial today